The criteria for coverage of denosumab (Prolia®) under the Alberta Health Services Drug Benefit Program have been expanded. Prolia® belongs to a class of osteoporosis treatment called a RANK ligand inhibitor. It reduces the risk of fractures of the spine, hip and other sites.
As fragility fractures are the most serious consequence of osteoporosis, and effective treatment is necessary to prevent future fractures, this is good news for patients in Alberta. Osteoporosis Canada congratulates the Alberta government.